Detalles de la búsqueda
1.
Early prostate-specific antigen response among Black and non-Black patients with advanced prostate cancer treated with apalutamide.
Future Oncol
; 18(32): 3595-3607, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36196743
2.
Medication adherence among patients with advanced prostate cancer using oral therapies.
Future Oncol
; 18(2): 231-243, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34730001
3.
Consideration of Potential Drug-Drug Interactions in Selection of FDA-Approved Drugs Indicated for Prostate Cancer.
Am J Ther
; 26(3): e422-e424, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30677005
4.
Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis.
Pharmacoecon Open
; 7(4): 617-626, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37074589
5.
Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study.
Urol Oncol
; 41(5): 252.e19-252.e27, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37080833
6.
Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide.
Urol Oncol
; 41(5): 253.e1-253.e9, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37061452
7.
Real-World Prostate-Specific Antigen Response and Treatment Adherence of Apalutamide in Patients With Non-Metastatic Castration-Resistant Prostate Cancer.
Urology
; 166: 182-188, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35318045
8.
Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study.
BMC Rheumatol
; 4: 16, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32266326
9.
Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis.
Clin Ther
; 41(6): 1080-1089.e5, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31122662
10.
Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors.
Curr Med Res Opin
; 35(10): 1751-1759, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31106607
11.
Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab.
Clinicoecon Outcomes Res
; 11: 99-110, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30679916
12.
Outcomes of infliximab dose escalation in patients with rheumatoid arthritis.
Clin Rheumatol
; 38(9): 2501-2508, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31049762
13.
Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels.
J Neurosci
; 27(16): 4385-95, 2007 Apr 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-17442823
14.
A descriptive analysis of real-world treatment patterns of innovator (Remicade®) and biosimilar infliximab in an infliximab-naïve Turkish population.
Biologics
; 12: 97-106, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30323555
15.
Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab.
Biologics
; 12: 127-134, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30498332
16.
Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept.
Patient
; 11(3): 361-369, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29427176
17.
A real-world, multi-site, observational study of infusion time and treatment satisfaction with rheumatoid arthritis patients treated with intravenous golimumab or infliximab.
J Med Econ
; 21(7): 724-731, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29718743
18.
Medication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide.
Am Health Drug Benefits
; 10(6): 296-303, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28975013
19.
Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy.
Am Health Drug Benefits
; 10(3): 143-153, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28626511
20.
Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs.
Patient Prefer Adherence
; 11: 947-958, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28572722